Search for Clinical Trial Results

Sponsored By

Carcinoma, Pancreatic Ductal - 23 Studies Found

Status Study
Completed Study Name: Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
Condition: Carcinoma, Pancreatic Ductal
Date: 2007-05-07
Interventions:
  • Drug: AG-013736 oral administr
Completed Study Name: According CTC to Compare the Influences of Different Methods to Remove the PDAC
Condition:
  • Carcinoma, Pancreatic Ductal
  • Circulating Tumor Cells

Date: 2015-05-14
Interventions:
  • Procedure: routine surgery To

Terminated Study Name: Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
Condition:
  • Resectable Pancreatic Cancer
  • Pancreatic Ductal Carcinoma
    • <
    Date: 2014-09-15
    Interventions:
    • Drug: FOLFIRINOX
    • Drug: Gemcitabine/nab-Pac
Completed Study Name: Continuous Monitoring on the General Ward
Condition:
  • Carcinoma, Pancreatic Ductal
  • Colorectal Neoplasms
  • Date: 2016-07-25
    Interventions:
    • Device: HealthPatch The Health
Terminated Study Name: Amatuximab for High Mesothelin Cancers
Condition:
  • Carcinoma, Pancreatic Ductal
  • Mesothelioma
  • Diabetes Mellitus, Adult-Onset
  • Diabetes Complications
  • Date: 2015-05-25
Active, not recruiting Study Name: Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
Condition: Metastatic Pancreatic Ductal Adenocarcinoma
Date: 2015-10-20
Interventions:
  • Drug: MEDI4736 in combination with nab-paclitaxel and gemcitabine

Active, not recruiting Study Name: Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma
Condition: Metastatic Pancreatic Ductal Adenocarcinoma
Date: 2015-08-27
Interventions:
  • Drug: MEDI4736 monotherapy MED
Completed Study Name: Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
Condition: Pancreatic Ductal Adenocarcinoma
Date: 2012-04-13
Interventions: Drug: INNO-206 INNO-206 at a total dose of 350 mg/m2 (260 mg/m2 doxorubicin equivalent) will be administ
Enrolling by invitation Study Name: Clinical Trial of Pancreatic Cancer in Stockholm.
Condition: Pancreatic Cancer
Date: 2014-06-11
Interventions: Procedure: Pancreatic Surgery Surgical removal of the pancreatic tumour (cancer) in the intervention gro
<<< Previous | Next >>>